MR
MRZM.US Marizyme Inc
- Market cap
- USD 39.5K
- P/E
- -
- P/B
- 0.10x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is MRZM.US undervalued?
Graham numberThe Graham number of Marizyme Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Marizyme Inc fundamental analysis
No fundamental analysis for Marizyme Inc yet.
Marizyme Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Marizyme Inc
Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase…
Full company profileMarizyme Inc financial statements
Marizyme Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 408K | 291K | 101K | 20.2K | 0.00 | 197K | 210K | 233K | 646K | 646K |
| Gross Profit | 177K | 82.7K | 14.3K | 113.00 | 0.00 | 139K | 130K | 179K | 239K | 239K |
| Operating Income | -1.19M | -182K | -125K | -247K | -1.06M | -5.80M | -8.82M | -13.0M | -34.1M | -34.1M |
| EBITDA | -961K | 48.2K | -125K | -249K | - | -5.21M | -10.8M | -34.5M | -55.4M | -55.4M |
| Net Income | -9.05M | -873K | -571K | -249K | -1.06M | -5.85M | -11.0M | -38.2M | -69.5M | -69.5M |
| EPS | -8.22 | -0.79 | -0.52 | -0.04 | -0.05 | -0.22 | -0.31 | -0.94 | -1.53 | -1.53 |
| Balance Sheet | ||||||||||
| Total Assets | 7.91M | 3.04M | 2.82M | 28.6M | 28.6M | 47.1M | 66.0M | 38.7M | 22.0M | 22.0M |
| Total Liabilities | 4.29M | 291K | 653K | 42.8K | 270K | 1.80M | 18.3M | 21.3M | 28.7M | 28.7M |
| Shareholders' Equity | 3.63M | 2.75M | 2.17M | 28.6M | 28.3M | 45.3M | 47.7M | 17.4M | -4.66M | -6.70M |
| Cash & Short-term Investments | 14.4K | 11.9K | 51.6K | 104.00 | 90.00 | 2.90M | 4.07M | 511K | 148K | 148K |
| Total Debt | 1.08M | 87.2K | -2.40K | - | - | 1.32M | 1.78M | 5.37M | 20.8M | 20.8M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -157K | 161K | 39.7K | -219K | -112K | -3.22M | -5.79M | -10.9M | -4.68M | -4.68M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 13.0K | 149K | 0.00 | 0.00 | 0.00 | 2.00 |
| Free Cash Flow | -157K | 161K | 39.7K | -219K | -125K | -3.37M | -5.79M | -10.9M | -4.68M | -4.68M |
| Ratios | ||||||||||
| ROE | -249.5% | -31.7% | -26.3% | -0.9% | -3.7% | -12.9% | -23.1% | -219.1% | - | - |
| ROA | -114.3% | -28.7% | -20.2% | -0.9% | -3.7% | -12.4% | -16.7% | -98.7% | -315.9% | -315.9% |
| Net Profit Margin | -2,219.2% | -299.8% | -563.9% | -1,232.2% | - | -2,965.0% | -5,230.2% | -16,346.2% | -10,767.8% | -10,767.8% |
| Debt to Equity | 0.30x | 0.03x | 0.00x | - | - | 0.03x | 0.04x | 0.31x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Marizyme Inc dividends
Marizyme Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:29 on Jul 27, 2018.
Who owns Marizyme Inc
- Insiders 34.96%
- Institutions 0.00%
- Public & others 65.04%
- Shares outstanding 132M
- Free float 85.6M
Marizyme Inc company profile
- Company name
- Marizyme Inc
- Ticker
- MRZM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Software
- Fiscal year end
- December
- Address
- 555 Heritage Drive, Jupiter, FL, United States, 33458
- Phone
- 561 935 9955
- Website
- marizyme.com
About Marizyme Inc
Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, and dental care and thrombosi, as well as MATLOC 1, a lab on chip digital device, which is under development for screening of individuals at risk for the development of chronic kidney disease. The company also engages in the development of MAR-FG-001, a fat grafting technology for fat grafting procedures. The company was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.
Marizyme Inc management
7- Mr. David L. Barthel M.B.A.CEO, Secretary & Director · born 1958
- Mr. George Kovalyov C.A., C.P.A.CFO, Treasurer & Director · born 1985
- Dr. Catherine J. Pachuk Ph.D.Executive VP & Chief Scientific Officer · born 1957
- Dr. Steven Scott Brooks FACC, M.B.A., M.D.Chief Medical Officer · born 1970
- Dr. Claudio Rigatto M.D.Chief Medical Officer of My Health Logic
- Kari JacobsonController
- Mr. Harrison Albert Ross C.F.A.Vice President of Finance · born 1993